Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio roundup of major events in the international biopharma industry over the past week, as covered by Scrip's global team.
Take a brief audio tour round Scrip's Five Must-Know Things, this time for the business week ended 9 October 2020.
In this edition, we look at the impact on clinical trials of President Trump’s treatment for COVID-19, a major acquisition by BMS, a planned EUA for Lilly’s covid antibody therapy, change at the top at Merck Research Labs, and a forward view on major new drug approvals expected in the coming months.
This and other Informa Pharma Intelligence podcasts are also now voice-accessible via Alexa smart speakers and the Alexa app, once set up as a skill. Just say “Alexa, Open Informa - Pharma Intelligence" and then ask for a specific podcast or topic.
Stories mentioned in this episode:
(Also see "Executive Privilege: How Giving Trump Special Access To Experimental COVID Treatment Could Backfire" - Scrip, 4 Oct, 2020.)
(Also see "BMS Buys MyoKardia, Plans To Use Eliquis Experience To Grow Mavacamten" - Scrip, 5 Oct, 2020.)
(Also see "Lilly Seeks EUA For COVID-19 Antibody, Unveils Positive Combo Data" - Scrip, 7 Oct, 2020.)
(Also see "Merck’s Perlmutter Is Retiring, Handing Over Keytruda To Li" - Scrip, 2 Oct, 2020.)
(Also see "12 Approvals To Look Out For In Q4" - Scrip, 7 Oct, 2020.)